NCT02715700View on ClinicalTrials.gov

Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

June 13, 2016

Study Completion Date

August 15, 2016

Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
DRUG

Methadone

Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.

DRUG

Doravirine

Doravirine 100 mg oral tablet once per day.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02715700 - Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045) | Biotech Hunter | Biotech Hunter